Diabetic segment remains the major contributing segment for us and in our endeavour to be more useful to our doctors, we have launched
Our brand Orvas is already a leader in the Atorvastatin market, and to further strengthen our product base in this segment,
To continue our prestigious relationship of 30 Years in Gastroenterology, we have introduced Cyraflora, a Supplemental Therapy to help maintain gut flora,
Another addition to the House of Antifungals is Amrosys – A Multifaceted Antifungal. This adds to our existing range of Fluconazole, Terbinafine, Itraconazole, Ketoconazole,
Orthopaedic segment is our inherent segment and we have been serving it for more than 3 decades. We have been leading the revolution in the segment with our diligent and pioneering efforts.